ArvindBagga India

• What Should a Clinician Know About CKD-MBD in 2025?
  LF01-01
  HanneJoergensen Speaker hsjorgensen@clin.au.dkDenmarkAarhus University
• CKD-MBD in Children and Young Adults: What's the Difference?
  LF01-02
  SukanyaGovindan Speaker sukanyagovindan@gmail.comIndiaMehta Children's Hospitals and MGM healthcare, Chennai, India
• Progress in CKD-driven Vascular Calcification: From Bench to Bedside
  LF01-03
  MarcVervloet Speaker Marc.Vervloet@radboudumc.nlNetherlandsRadboud University Medical center, The Netherlands
• How to Use Serum Biomarkers for Optimal Management of CKD-MBD
  LF01-04
  SandroMazzaferro Speaker sandro.mazzaferro@uniroma1.itItalySapienza University of Rome, Italy
• Q&A
  LF01-05

• Outcomes From the ISN Haemolytic Uraemic Syndromes Forum: A Comprehensive Review
  IK1001-01
  DavidKavanagh Speaker David.Kavanagh@newcastle.ac.ukUnited KingdomNational Renal Complement Therapeutics Centre
• Differential Diagnosis and Treatment of TMAs in Pregnancy
  IK1001-02
  ShilpanjaliJesudason Speaker shilpa.jesudason@sa.gov.auAustraliaRoyal Adelaide Hospital and University of Adelaide, Australia
• Factor H Autoantibodies in aHUS
  IK1001-03
  AditiSinha Speaker aditisinhaaiims@gmail.comIndiaDepartment of Pediatrics, All India Institute of Medical Sciences
• aHUS in Paediatric Populations
  IK1001-04
  Lap Tak Alison MA Speaker maalison2000@gmail.comHong Kong, ChinaHong Kong Children\'s Hospital
• Q&A
  IK1001-05